Both the innate and adaptive immune system reactivated. Stated in the lower left section of the poster, I believe that this is the absolute key to why bavi has been producing the long survival times in our solid tumor cancer trials.
Just to the right of that important understanding, there is a graph of tumor volume running against 14 weeks of treatment time using a control and PGN635 (fully human bavituximab) alone and in combinations.
Look at the PGN635 plus docetaxel combination showing much lower tumor volumes. I also notice two distinct tendencies of reduced tumor volume growth using this combination treatment: one after 9 weeks, and another after 13 weeks.
Could these two markers be signatures of innate and/or adaptive immunity starting to kick in?
I would venture that this may be what we are seeing here.
Market Data 
Markets 
AI
